Adagio Therapeutics picks up $80m Series B

Waltham, Massachusetts-based Adagio Therapeutics Inc, a developer of best-in-class antibodies, has raised $80 million in Series B financing.

Waltham, Massachusetts-based Adagio Therapeutics Inc, a developer of best-in-class antibodies, has raised $80 million in Series B financing. GV led the round with participation from Polaris Partners, Mithril Capital, Fidelity Management & Research Company, LLC, OrbiMed, Population Health Partners and Omega Funds.

Source: Press Release